3.3.2.10: soluble epoxide hydrolase
This is an abbreviated version!
For detailed information about soluble epoxide hydrolase, go to the full flat file.
Word Map on EC 3.3.2.10
-
3.3.2.10
-
epoxyeicosatrienoic
-
arachidonic
-
diol
-
s-transferase
-
hydrolases
-
hypertension
-
benzoapyrene
-
epoxygenase
-
styrene
-
dihydroxyeicosatrienoic
-
enantioselectivity
-
phenobarbital
-
dhets
-
trans-stilbene
-
leukotriene
-
eicosanoids
-
drug-metabolizing
-
cyp1a1
-
3-methylcholanthrene
-
o-deethylase
-
oxylipins
-
xenobiotic-metabolizing
-
dihydrodiols
-
enantiopure
-
ethoxyresorufin
-
lta4
-
glycidyl
-
arene
-
urea-based
-
cyclohexene
-
ethoxycoumarin
-
medicine
-
beta-naphthoflavone
-
oxirane
-
20-hydroxyeicosatetraenoic
-
udp-glucuronyltransferase
-
20-hete
-
cyp2j2
-
udp-glucuronosyl
-
1-naphthol
-
aminopyrine
-
edhfs
-
analysis
-
radiobacter
-
3-methylcholanthrene-treated
-
butadiene
-
udpgt
-
hydroxyeicosatetraenoic
-
epichlorohydrin
-
aldrin
-
synthesis
-
pentoxyresorufin
-
drug development
-
agriculture
-
adamantyl
-
pharmacology
- 3.3.2.10
-
epoxyeicosatrienoic
-
arachidonic
- diol
- s-transferase
- hydrolases
- hypertension
-
benzoapyrene
- epoxygenase
- styrene
-
dihydroxyeicosatrienoic
-
enantioselectivity
- phenobarbital
-
dhets
- trans-stilbene
-
leukotriene
-
eicosanoids
-
drug-metabolizing
- cyp1a1
- 3-methylcholanthrene
-
o-deethylase
- oxylipins
-
xenobiotic-metabolizing
-
dihydrodiols
-
enantiopure
-
ethoxyresorufin
- lta4
-
glycidyl
- arene
-
urea-based
- cyclohexene
-
ethoxycoumarin
- medicine
- beta-naphthoflavone
-
oxirane
-
20-hydroxyeicosatetraenoic
-
udp-glucuronyltransferase
- 20-hete
- cyp2j2
-
udp-glucuronosyl
- 1-naphthol
- aminopyrine
-
edhfs
- analysis
- radiobacter
-
3-methylcholanthrene-treated
- butadiene
-
udpgt
-
hydroxyeicosatetraenoic
- epichlorohydrin
- aldrin
- synthesis
-
pentoxyresorufin
- drug development
- agriculture
-
adamantyl
- pharmacology
Reaction
Synonyms
AnEH, BNSEH1, CEH, Cterm-EH, Cytosolic epoxide hydrolase, EC 3.1.3.76, EC 3.3.2.3, EC 4.2.1.63, EC 4.2.1.64, EET-metabolizing enzyme, EH, EH3, EPHX2, EPHX3, epoxide hydrolase 1, epoxide hydrolase 2, epoxide hydrolase-3, epoxyeicosatrienonic acid-metabolizing enzyme, EPXH1, EPXH2, EPXH2B, hepoxilin hydrolase, hsEH, mEH, More, PNSO hydrolase, PsEH, s-EH, SEH, soluble epoxide hydrolase, soluble-type epoxide hydrolase, SPEH1, SPEH2, TESO hydrolase, TSO hydrolase
ECTree
Advanced search results
Application
Application on EC 3.3.2.10 - soluble epoxide hydrolase
Please wait a moment until all data is loaded. This message will disappear when all data is loaded.
agriculture
-
the isolation of BNSEH1 will facilitate metabolic studies of resistance and seed oil modification in the important oilcrop Brassica napus
analysis
-
development of a high-throughput screen assay for soluble epoxide hydrolase inhibition using (3-phenyl-oxiranyl)-acetic acid cyano-(6-methoxy-naphthalen-2-yl)-methyl ester as a substrate. Assay is accurate and precise
drug development
medicine
pharmacology
synthesis
additional information
-
sEH may have tissue- or cell-type-specific functionality
sEH is a cross-functional target with the potential for therapeutic utility in the areas of hypertension, inflammation, and organ protection
drug development
sEH is a target for drug design, since inhibition of sEH leads to an increase in circulating levels of epoxyeicosatrienoic acids, resulting in the potentiation of their in vivo pharmacological properties
drug development
sEH is a target for drug design, since inhibition of sEH leads to an increase in circulating levels of epoxyeicosatrienoic acids, resulting in the potentiation of their in vivo pharmacological properties
drug development
soluble epoxide hydrolase (sEH) is a potential target for the treatment of inflammation and hypertension
drug development
-
the enzyme is an important therapeutic target for chronic diseases such as hypertension, diabetes and inflammation
medicine
-
the enzyme is a target for regulation of blood pressure, and inhibition of inflammation, atherosclerosis, kidney failure, and cancer progression
medicine
-
the enzyme is a therapeutic target for control of blood pressure
medicine
-
the enzyme is a therapeutic target in therapeutic intervention in renal hydrodynamic regulation and blood pressure control
medicine
-
expression of soluble epoxide hydrolase is significantly lower in stroke-prone than in stroke-resitant rats. Identification of 3 polymorphisms that significantly influence promoter transcriptional activity in vitro
medicine
-
kinetic analysis of the effects of human enzyme polymorphisms on the N-terminal phosphatase activity of soluble epoxide hydrolase activity
medicine
-
mice with targeted disruption of the Ephx2 gene coding for soluble epoxide hydrolase have normal heart anatomy and basal contractile function, but have higher fatty acid epoxide:diol ratios in plasma and cardiomyocytes cell culture media. The heart have improved recovery of left ventricular developed pressure and less infarction after 20 min ischemia, compared with wild-type. Perfusion with 14,15-epoxyeicosa-5(Z)-enoic acid before ischemia abolishes this cardioprotective phenotype. Enzyme null mice exhibit increased cardiac expression of glycogen synthase kinase-3beta phosphoprotein after ischemia
medicine
-
ovariectomized female rats with and without estradiol replacement undergoing 2-h middle cerebral artery occlusion. Estradiol reduces basal and post-ischemic soluble epoxide hydrolase expression. Middle cerebral artery occlusion strongly induces mRNA levels of tumor necrosis factor-alpha, interleukin 6, and interleukin 1beta, which is attenuated in enzyme knock-outs, but not by enzyme inhibitors
medicine
-
semi-quantitative evaluation of staining intensity of soluble epoxide hydrolase and several cytochromes in different malignant tissues. Soluble epoxide hydrolase expression in renal and hepatic malignant neoplasms and surrounding non-malignant tissues is significantly decreased, whereas expression is increased in seminoma
medicine
-
genetic variation in or near the EPHX2 gene contributes to the risk of ischemic stroke
medicine
-
sEH inhibitors may be useful in the treatment of patients with atherosclerotic cardiovascular disease
medicine
-
sEH inhibitors may be useful in the treatment of patients with atherosclerotic cardiovascular disease
medicine
-
sEH is a target for the treatment of hypertension and vascular inflammation
medicine
-
sEH is a target for the treatment of hypertension, inflammatory diseases, pain, diabetes, and stroke
medicine
sEH is a target for the treatment of hypertension, inflammatory diseases, pain, diabetes, and stroke
medicine
-
soluble epoxide hydrolase inhibition and gene deletion are protective against myocardial ischemia-reperfusion injury in vivo and reduce the infarct size
medicine
-
soluble epoxide hydrolase is a susceptibility factor for heart failure
medicine
-
soluble epoxide hydrolase is a susceptibility factor for heart failure, EPHX2 mRNA expression is down-regulated in individuals with heart failure
medicine
-
soluble epoxide hydrolase plays an essential role in angiotensin II-induced cardiac hypertrophy
medicine
-
soluble epoxide hydrolase plays an essential role in angiotensin II-induced cardiac hypertrophy
medicine
-
the activity of sEH plays a significant role in determining the magnitude of acute hypoxic vasoconstriction
medicine
-
the presence of the rs1042032 variant allele (polymorphism of 3'-untranslated region A/G) in EPHX2 is associated with a protective role for allograft function
medicine
-
sEH enzyme gains considerable attention as a therapeutic target for cardiovascular diseases
medicine
sEH is a potential therapeutic target in the treatment of ischemic stroke
medicine
sEH is a potential therapeutic target in the treatment of ischemic stroke. Treatment of acute ischemic stroke with sEH inhibition, overview
medicine
since the metabolism of EETs by sEH reduces or eliminates their bioactivity, inhibition of sEH has become a therapeutic strategy for hypertension and inflammation
medicine
-
inhibition of soluble epoxide hydrolase by orally active inhibitor 12-(3-adamantan-1-yl-ureido)-dodecanoic acid is effective in persistently reducing blood pressure in female spontaneously hypertensive rats when 12-(3-adamantan-1-yl-ureido)-dodecanoic acid is applied during the perinatal phase. This is accompanied by marked increases in major renal arachidonic acid epoxides and decreases in renal lipoxygenase products of arachidonic acid. Early inhibition of SEH induces a delayed increase in renal 5-HETE at 24 weeks, in contrast to a decrease at 2 weeks. Inhibition of SEH in female spontaneously hypertensive rats from 8 to 12 weeks does not reduce blood but causes profound decreases in renal 15(S)-HETrE, LTB4, TBX2, 5-HETE, and 20-HETE and increases in TriHOMEs. In male spontaneously hypertensive rats, blood pressure reduction after perinatal AUDA is transient
medicine
-
intratracheal instillation of benzo(a)pyrene significantly suppresses NF-kappaB translocation, sEH, thioredoxin reductase and catalase activities in lung tissue. Glycyrrhizic acid oral administration at 50 and 100 mg/kg body weight significantly shows protection of lung epithelium by suppression of caspases activities in lung tissue and reduction of total protein, total cells, elastase activity. Results indicate a strong correlation between amelioration of sEH and thioredoxin reductase activities, and NF-kappaB activation
medicine
-
modulation of the vascular response mediated through adenosine A2A receptor using aortas from mice fed a 4% NaCl high salt or 0.45% NaCl low salt diet for 4-5 weeks. Compared with NS, HS vessels show increased CYP2J2 and A2A adenosine receptor expression but decreased sEH, CYP4A, and A1 adenosine receptor expression. Data suggest that in mice fed low salt containing diet, upregulation of arterial A1 receptor causes vasoconstriction via increased sEH and CYP4A proteins. In mice fed high salt-containing diet, upregulation of A2A receptor protein triggers vascular relaxation through ATP-sensitive channels via upregulation of CYP2J2 enzyme
medicine
-
relative expression of sEH is lower at both the mRNAand protein levels in HepG2 cells than in other cells with the same amount of total RNA or protein loaded. Transcription factor SP-1 is involved in the decrease in the transcription of sEH as a result of DNA methylation in HepG2 cells, which might contribute to epigenetic mechanism-induced carcinogenesis in hepatocytes
medicine
-
sEH is synthesized in adipocytes and expression levels increase upon differentiation of 3T3-L1 preadipocytes. Although normalized sEH mRNA and protein levels do not differ in the fat pads from mice receiving a regular or a high-fat diet, total adipose sEH activity is higher in the obese mice. Peroxisome proliferator-activated receptor gamma agonists increase the expression of sEH in mature 3T3-L1 adipocytes in vitro and in adipose tissue in vivo
medicine
-
study on the mechanism behind adenosine-induced vascular response in high salt-fed eNOS+/+ and eNOS-/- mice. Compared to low salt diet, high salt diet increases CYP2J2 in eNOS+/+ and eNOS-/- mice, but decreases sEH in eNOS+/+ and eNOS-/- animals. Similarly, CYP4A decreases in high salt-fed-eNOS+/+ and -eNOS-/- animals. Data suggest that low salt diet causes reduced-vasodilation in both eNOS+/+ and eNOS-/- background via sEH and CYP4A
medicine
because of its central physiological role in disease states such as cardiac hypertrophy, diabetes, hypertension, and pain, the enzym is used as a therapeutic target
medicine
-
brain microvascular endothelial cells from female brain are more resistant to ischemic injury compared to male cells due to lower expression of soluble epoxide hydrolase
medicine
-
treatment with soluble epoxide hydrolase inhibitors can reduce acute kidney injury
medicine
-
upregulation of the enzyme in proximal tubular cells in chronic proteinuric kidney diseases may mediate proteinuria-induced renal damage, while enzyme inhibition by increasing renal eicosanoid levels can prevent the progression of chronic proteinuric kidney diseases
-
the enzyme is a key target in treatment of acute systemic hypotension
pharmacology
-
the enzyme is a target for inhibition in therapy of disorders resulting from hypertension and vascular inflammation
pharmacology
-
the enzyme is a target for inhibition in therapy of disorders resulting from hypertension and vascular inflammation
pharmacology
SEH inhibition might have a potential for flow-induced vascular remodeling and neointimal formation
pharmacology
the enzyme is a promising therapeutic strategy for cardiovascular disease
-
the enzyme may be a good biocatalyst for the preparation of enantiopure epoxides or diols
synthesis
-
potential as biocatalyst for the preparation of enantiopure epoxides
synthesis
-
potential as biocatalyst for the preparation of enantiopure epoxides
synthesis
-
the enantioselective enzyme is useful in production of chiral substances, e.g. production of (2R,3S)-ethyl 3-phenylglycidate with 95% enantiomeric excess and 26% yield in 12 h from 0.2% (w/v) of the racemat by whole cells of Pseudomonas sp. strain BZS21, maximal activity with dimethyl formamide as co-solvent
synthesis
the enzyme is useful for enantioselective bio-organic synthesis of chiral substances
synthesis
-
enantioselective hydrolysis of racemic styrene derivative via attack of the benzylic position results in formation of the correspponding (R)-diol with enantiomeric excess of up to 96% and more than 90% conversion
synthesis
-
highly enantioselective synthesis of chiral 1,2 diols from epoxides in ionic liquid [bmim][PF6] or [bmim][Tf2N] in presence of 10% water
synthesis
-
the enzyme is useful for enantioselective bio-organic synthesis of chiral substances
-
synthesis
-
the enantioselective enzyme is useful in production of chiral substances, e.g. production of (2R,3S)-ethyl 3-phenylglycidate with 95% enantiomeric excess and 26% yield in 12 h from 0.2% (w/v) of the racemat by whole cells of Pseudomonas sp. strain BZS21, maximal activity with dimethyl formamide as co-solvent
-